International Tables for Crystallography (2019). Vol. H. ch. 7.5, pp. 767-781
https://doi.org/10.1107/97809553602060000979

Chapter 7.5. Powder diffraction and pharmaceuticals

Contents

  • 7.5. Powder diffraction and pharmaceuticals  (pp. 767-781) | html | pdf | chapter contents |
    J. Bernstein and S. M. Reutzel-Edens
    • 7.5.1. Introduction  (p. 767) | html | pdf |
    • 7.5.2. Some basic background and references  (p. 767) | html | pdf |
    • 7.5.3. Identification and characterization  (p. 767) | html | pdf |
      • 7.5.3.1. Polymorphs, salts, solvates, co-crystals  (pp. 767-768) | html | pdf |
      • 7.5.3.2. Indexing  (pp. 768-769) | html | pdf |
      • 7.5.3.3. Crystal structure solution  (p. 769) | html | pdf |
    • 7.5.4. Quantitation of mixtures by traditional and Rietveld methods  (pp. 769-771) | html | pdf |
    • 7.5.5. Characterization of amorphous materials  (pp. 771-773) | html | pdf |
    • 7.5.6. Quality control and regulatory aspects  (p. 773) | html | pdf |
    • 7.5.7. Creating and protecting intellectual property  (pp. 773-777) | html | pdf |
      • 7.5.7.1. Crystal habit  (pp. 776-777) | html | pdf |
    • 7.5.8. Counterfeit medicines  (pp. 777-778) | html | pdf |
    • 7.5.9. Concluding remarks  (p. 778) | html | pdf |
    • References | html | pdf |
    • Figures
      • Fig. 7.5.1. Schematic highlighting the many areas across the pharmaceutical industry that are strongly impacted by solid-state science and technology  (p. 767) | html | pdf |
      • Fig. 7.5.2. Profile plots for the Rietveld refinement of fexofenadine hydrochloride  (p. 769) | html | pdf |
      • Fig. 7.5.3. Profile plots of the Rietveld refinement of heat-treated carbamazepine, showing an improved fit over pure form I (space group [P\bar 1], top) obtained by modelling the X-ray powder diffraction pattern with ∼4% form III (space group P21/c) in form I (bottom) [from Antonio et al  (p. 771) | html | pdf |
      • Fig. 7.5.4. X-ray powder diffraction patterns of indomethacin, showing progressive loss of long-range order (crystallinity) with extended grinding  (p. 772) | html | pdf |
      • Fig. 7.5.5. PDF traces of crystalline anhydrate (AH), crystalline dihydrate (DH), milled (M) and quench-cooled (Q) samples of amlodipine besylate [from Bøtker et al  (p. 773) | html | pdf |
      • Fig. 7.5.6. XRPD traces of the two pure forms of ranitidine hydrochloride [from Agatonovic-Kustin et al  (p. 774) | html | pdf |
      • Fig. 7.5.7. Synchrotron XRPD patterns of ad hoc mixtures of salicylic acid and paracetamol: the limit of detection of 0.1 wt% for the minor component achieved with a conventional optics setup was improved by a factor of 10 to 0.01 wt% with careful optimization of the beamline optics  (p. 775) | html | pdf |
      • Fig. 7.5.8. Comparison of the measured XRPD patterns for two different habits of aspartame  (p. 777) | html | pdf |
      • Fig. 7.5.9. The comparison of diffraction patterns of a counterfeit `Viagra' tablet and the original drug (shown as the thick lines in grey) taken with the coatings removed [from Maurin et al  (p. 778) | html | pdf |